XOMA to Announce First Quarter 2015 Financial Results and Host Conference Call on May 7
01 May 2015 - 3:00AM
XOMA Corporation (Nasdaq:XOMA), a leader in the discovery and
development of antibody therapeutics, announced the Company will
host a conference call on Thursday, May 7, 2015, at 4:30 p.m.
Eastern time to discuss first quarter 2015 financial results and
provide an update on gevokizumab's global clinical programs.
The webcast can be accessed via the Investors & Media
section of XOMA's website at http://investors.xoma.com/events.cfm
and will be available for replay until close of business on August
7, 2015. Telephone numbers for the live audiocast are 877-369-6589
(U.S./Canada) and 408-337-0122 (international).
About XOMA Corporation
XOMA Corporation is a leader in the discovery and development of
therapeutic antibodies. The Company's innovative product candidates
are the result of the Company's expertise in developing
ground-breaking monoclonal antibodies, including allosteric
modulating antibodies, which have created new opportunities to
potentially treat a wide range of human diseases. XOMA is
developing its lead product gevokizumab (IL-1 beta modulating
antibody) with Servier through a global Phase 3 program for
Behçet's disease uveitis and non-infectious uveitis. XOMA also has
an ongoing Phase 3 study of gevokizumab in pyoderma gangrenosum.
Additionally, XOMA's scientific research has produced the XMet
platform, which consists of three classes of Selective Insulin
Receptor Modulators (SIRMs) antibodies. XOMA 358, the lead antibody
in the XMetD program, is an allosteric modulating monoclonal
antibody that reduces the binding of insulin to its receptor,
down-regulates insulin signaling and could have a major effect on
the treatment of abnormal metabolic states. XOMA 358 recently
completed Phase 1 testing. For more information, visit
www.xoma.com.
CONTACT: XOMA Corporation
Company and Investor Contact:
Ashleigh Barreto
510-204-7482
barreto@xoma.com
Juliane Snowden
The Oratorium Group, LLC
jsnowden@oratoriumgroup.com
Media contact:
Ryan Flinn
W2O Group
415-946-1059
rflinn@w2ogroup.com
XOMA (NASDAQ:XOMA)
Historical Stock Chart
From Apr 2024 to May 2024
XOMA (NASDAQ:XOMA)
Historical Stock Chart
From May 2023 to May 2024